NIMODIPINE STADAFARMA 30 mg FILM-COATED TABLETS

Introduction

Package Leaflet: Information for the User

Nimodipine Stadafarma 30 mg Film-Coated Tablets

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the Package Leaflet:

1. What is Nimodipine Stadafarma and what is it used for.
2. What you need to know before you take Nimodipine Stadafarma.
3. How to take Nimodipine Stadafarma.
4. Possible side effects.
5. Storage of Nimodipine Stadafarma.
6. Contents of the pack and further information.

1. What is Nimodipine Stadafarma and what is it used for

Nimodipine Stadafarma is a medicine that contains the active substance nimodipine and belongs to a group of medicines called calcium antagonists. These substances are able to dilate arteries and prevent them from contracting, ensuring that the brain receives enough oxygen.

Nimodipine is used to prevent neurological damage caused by lack of blood flow due to the contraction of cerebral arteries after a subarachnoid hemorrhage (a type of brain bleeding caused by the rupture of an aneurysm, which is an abnormal dilation or bulge of a portion of an artery where the wall is weakened).

2. What you need to know before you take Nimodipine Stadafarma

Do not take Nimodipine Stadafarma

• If you are allergic (hypersensitive) to nimodipine or any of the other ingredients of this medicine listed in section 6.
• If you are taking any of the following medicines for epilepsy: phenobarbital, phenytoin, or carbamazepine.
• If you are taking rifampicin (an antibiotic used to treat tuberculosis).
• If you have severe liver disease (e.g., cirrhosis).
• If you have generalized cerebral edema (increased amount of fluid in the brain).
• If you have severe intracranial hypertension (significant increase in pressure inside the head).

Warnings and precautions

Consult your doctor or pharmacist before starting to take this medicine.

• If you have blood pressure disorders or are being treated to lower your blood pressure.
• If you have kidney or liver disease.
• If you have had a head injury that caused intracranial bleeding.
• If you have heart problems, e.g., cardiac arrhythmias and heart failure (a condition in which the heart is unable to pump enough blood to meet the body's needs), in these circumstances, your doctor will perform periodic checks.
• If you weigh less than 70 kg.

In all these situations, your doctor will need to perform a series of checks to adjust the dose of nimodipine appropriately.

If you are taking any of the medicines indicated in the section "Taking Nimodipine Stadafarma with other medicines," your doctor will monitor your blood pressure and adjust the dose of nimodipine.

Taking Nimodipine Stadafarma with other medicines

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

Certain medicines may interact with this medicine; in these cases, your doctor will need to adjust the dose or interrupt treatment with one of the medicines. This is especially important when taking:

• Rifampicin (a medicine for the treatment of tuberculosis), as it may decrease the efficacy of nimodipine (see section "Do not take Nimodipine Stadafarma").
• Medicines for treating epilepsy, such as phenytoin, phenobarbital, or carbamazepine, with chronic administration prior to treatment with nimodipine (see section "Do not take Nimodipine Stadafarma").
• Medicines to lower blood pressure, as they may enhance the hypotensive effect of nimodipine.
• Cimetidine (a medicine used in the management of stomach ulcers) or valproic acid (used in the treatment of epilepsy), as they may enhance the hypotensive effect of nimodipine.
• Antibiotics (medicines for treating infections) such as erythromycin, quinupristin, and dalfopristin.
• Antiretroviral medicines (used in the treatment of HIV infection) such as ritonavir and zidovudine.
• Antifungal medicines (used for the treatment of fungal infections) such as ketoconazole.
• Medicines for depression, such as nefazodone, fluoxetine, and nortriptyline.

Taking Nimodipine Stadafarma with food and drinks

It is not recommended to take grapefruit juice with nimodipine, as it may alter its efficacy. Nimodipine should be taken outside of meals.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Nimodipine should not be used during pregnancy and breastfeeding, unless prescribed by a doctor. If it is essential to use nimodipine, your doctor will assess the possibility of administering this medicine.

Driving and using machines

If you feel dizzy after taking nimodipine, you should not drive vehicles or operate machinery, especially if you consume alcohol during treatment, so you should not drink alcohol during treatment.

3. How to take Nimodipine Stadafarma

Follow exactly the administration instructions of this medicine indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

The recommended dose to prevent neurological damage due to lack of blood flow caused by the contraction of cerebral arteries after a subarachnoid hemorrhage should be (after a previous infusion of nimodipine 0.2 mg/ml solution for infusion for 5 to 14 days) a daily dose of 2 tablets of this medicine 6 times a day (6 times x 60 mg of nimodipine daily), up to a maximum total period of approximately three weeks. The interval between administrations should not be less than four hours.

Generally, the tablet is taken whole without chewing with the help of a little liquid (e.g., a glass of water), except for grapefruit juice. Nimodipine should be taken outside of meals (see section "Taking Nimodipine Stadafarma with food and drinks").

Liver disease:You should not take this medicine if you have severe liver disease (see section "Do not take Nimodipine Stadafarma"). Inform your doctor if you suffer or have suffered from any liver disease so that the doctor can adjust the dose accordingly.

Kidney disease:Inform your doctor if you suffer or have suffered from any kidney disease, as it may be necessary to adjust the dose of nimodipine.

Use in children and adolescents: The use of nimodipine in children and adolescents is not recommended.

Your doctor will indicate the duration of treatment with nimodipine. Do not stop treatment before or abruptly, as it may be harmful to the evolution of your disease.

If you take more Nimodipine Stadafarma than you should

If you have taken more nimodipine than you should, consult your doctor or pharmacist immediately.

The symptoms you may experience are: marked decrease in blood pressure, increase or decrease in heart rate, gastrointestinal disorders (e.g., nausea), and effects on the central nervous system.

In case of overdose or accidental ingestion, consult the Toxicology Information Service. Phone 91 562 04 20.

If you forget to take Nimodipine Stadafarma

Do not take a double dose to make up for forgotten doses.

In case of forgetting a dose, you should take the tablet as soon as possible, continuing treatment as prescribed. However, when it is close to the next dose, it is better not to take the forgotten tablet and take the next one at the scheduled time.

If you stop taking Nimodipine Stadafarma

If you have any doubts about the use of this product, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Side effects, more or less troublesome, occur in some patients, especially at the start of treatment.

The following possible side effects have been reported:

Common (may affect up to 1 in 10 people)

• hypotension (low blood pressure), vasodilation (widening of blood vessels)
• difficult digestion, abdominal cramps
• dermatitis, eruptions, acne
• muscle cramps

Uncommon (may affect up to 1 in 100 people)

• hot flashes
• changes in heart rate: bradycardia (decrease), tachycardia (increase), palpitations, heart failure
• anemia, decrease in blood platelets
• peripheral edema (swelling of legs or hands), fainting, hematomas (bruises), vasoconstriction (narrowing of blood vessels), and increased blood pressure, thrombosis
• diarrhea, constipation, vomiting, flatulence, gastrointestinal bleeding
• headache, dizziness, involuntary movements, tremor, depression, sweating
• breathing difficulties
• itching, urticaria, petechiae (small purple spots)
• allergic reaction
• hepatitis, jaundice (yellowing of skin and mucous membranes)

Rare (may affect up to 1 in 1,000 people)

• decrease in sodium levels in the blood
• ileus (intestinal obstruction)
• increase in liver enzyme values, indicators of liver function, (including increased alkaline phosphatase and lactate dehydrogenase)

Frequency not known (cannot be estimated from the available data)

• nausea
• decrease in blood pressure, especially when the initial value is high, gamma-

glutamyltransferase increased, transaminases elevated (a type of liver enzyme indicator of liver function)

• low oxygen levels in body tissues

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Nimodipine Stadafarma

Keep this medicine out of the sight and reach of children.

Remove the tablet from the original packaging immediately before administration.

Do not use this medicine after the expiry date which is stated on the packaging after EXP. The expiry date is the last day of the month shown.

Medicines should not be disposed of via wastewater or household waste. Return the packaging and any unused medicine to a pharmacy for safe disposal. Ask your pharmacist how to dispose of medicines no longer required. This will help to protect the environment.

6. Contents of the pack and further information

Composition of Nimodipine Stadafarma

• The active substance is nimodipine. Each film-coated tablet contains 30 mg of nimodipine.
• The other ingredients are microcrystalline cellulose (E-460), pregelatinized corn starch, crospovidone, povidone (E-1201), magnesium stearate (E-572), hydroxypropylmethylcellulose, polyethylene glycol 400, titanium dioxide (E-171).

Appearance of the product and packaging contents

The film-coated tablets are white or slightly yellowish, round, biconvex, scored on one side, and have the letter B on the other side. Free of visible impurities.

Nimodipine Stadafarma 30 mg film-coated tablets are available in packs of 30 and 100 tablets.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder:

Laboratorio STADA, S.L.

Frederic Mompou, 5

08960 Sant Just Desvern (Barcelona) Spain

info@stada.es

Manufacturer:

Laboratorios Medicamentos Internacionales, S.A.

Solana, 26

28850 Torrejón de Ardoz (Madrid) Spain

Date of the last revision of this leaflet:September 2024

Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es.